Moderna Stock is Soaring. Is It Too Late to Buy?

Moderna’s stock has recently surged by over 70% due to its broad pipeline of infectious disease vaccines, oncology, and rare disease candidates, following a decline in demand for its coronavirus vaccine. While the company is working towards new growth phases, including a promising cancer vaccine and a flu vaccine candidate, it reported a net loss in 2025, indicating that investors need to be patient. An analyst suggests waiting for a dip before purchasing Moderna shares, despite optimism about its future.